Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Jan 28, 2025
Emerging Company Profile
Isomab: Rebalancing VEGF-A isoforms to promote blood vessel formation
University of Nottingham spinout is developing an antibody for peripheral artery disease that turns VEGF’s cancer paradigm on its head
BioCentury | Dec 4, 2024
Product Development
Confidence in masked T cell engagers builds with Janux update
Also in BioCentury’s Clinical Report: Cartesian’s autoimmune CAR T durability, Roivant’s miss, Novocure’s pancreatic cancer data, and more
BioCentury | Nov 8, 2024
Deals
With Eylea rival in clinic, once-stealthy Kalaris finds public path via merger
Samsara-backed start-up launched by former Genentech colleagues picks AlloVir as vehicle to reach NASDAQ
BioCentury | Feb 2, 2024
Market Access
Manufacturers should think twice before developing a self-administered biosimilar
Samsung Bioepis report says Humira has 97% of the adalimumab market almost a year after it lost exclusivity
BioCentury | Nov 1, 2023
Regulation
FDA illuminates the single trial path
How one trial plus confirmatory evidence can add up to approval
BioCentury | Aug 30, 2023
Regulation
Aug. 30 Quick Takes: With Embark acquisition, Novo gains another obesity asset
Plus: Epigenome editing company Epigenic raises $32M series A and updates from Outlook, InflaRx, Zealand and FDA
BioCentury | May 26, 2023
Product Development
TIGIT and LAG3 back in the spotlight at ASCO 2023
Phase I data reignite enthusiasm for checkpoint inhibitors, but will the results reproduce?
BioCentury | Feb 11, 2023
Product Development
The latest twist in the overall survival debate
It’s becoming harder to show an overall survival benefit, and regulatory expectations are starting to change
BioCentury | Jan 20, 2023
Market Access
Jan. 19 Quick Takes: Average price cuts of 60% for new listings on China’s NRDL
Plus: Shoreline buying Editas NK assets and updates from Intercept, Roche, Seagen and more
Items per page:
1 - 10 of 1670